- What is TMS Therapy
- Neurostar Clinical Research
- NeuroStar TMS Therapy System
- NeuroStar Service & Support
Clinical trials have proven the safety of NeuroStar TMS Therapy® in the treatment of patients with major depressive disorder and who have had an inadequate response to initial antidepressant medication.
Treatment with NeuroStar TMS Therapy caused few side effects and was generally well tolerated by patients. The most common side effect reported during clinical trials was scalp pain or discomfort — generally mild to moderate and occurring less frequently after the first week of treatment.
Less than 5% of patients discontinued treatment with NeuroStar TMS Therapy due to adverse events.
There is a low risk of seizure with TMS Therapy. The estimated risk of seizure under ordinary clinical use is approximately 1 in 30,000 treatments (0.003% of treatments) or 1 in 1000 patients (0.1% of patients).
Patients should be carefully monitored for worsening symptoms, signs or symptoms of suicidal behavior and/or unusual behavior. Families and caregivers should also be aware of the need to observe patients and notify their treatment provider if symptoms worsen.
NeuroStar TMS Therapy is contraindicated in patients with implanted metallic devices or non-removable metallic objects in or around the head or for patients who have certain device implants such as deep brain stimulators, cochlear implants and vagus nerve stimulators. NeuroStar TMS Therapy should be used with caution in patients with implants controlled by physiological signals. This includes pacemakers and implantable cardioverter defibrillators (ICDs).